NASDAQ:OPT Opthea (OPT) Stock Price, News & Analysis $2.24 +0.04 (+1.82%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.15▼$2.2750-Day Range$1.86▼$3.4652-Week Range$1.60▼$4.40Volume14,454 shsAverage Volume24,522 shsMarket Capitalization$130.82 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Opthea alerts: Email Address Opthea MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside525.0% Upside$14.00 Price TargetShort InterestHealthy0.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.04Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.53) to ($2.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.59 out of 5 starsMedical Sector499th out of 936 stocksBiological Products, Except Diagnostic Industry72nd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingOpthea has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOpthea has received no research coverage in the past 90 days.Read more about Opthea's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.13% of the outstanding shares of Opthea have been sold short.Short Interest Ratio / Days to CoverOpthea has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Opthea has recently decreased by 4.38%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOpthea does not currently pay a dividend.Dividend GrowthOpthea does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPT. Previous Next 2.8 News and Social Media Coverage News SentimentOpthea has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Opthea this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Opthea insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Opthea is held by insiders.Percentage Held by Institutions55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Opthea's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Opthea are expected to grow in the coming year, from ($2.53) to ($2.03) per share.Read more about Opthea's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Opthea Stock (NASDAQ:OPT)Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Read More OPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPT Stock News HeadlinesJuly 24 at 10:55 PM | msn.com'Blockbuster opportunity': This speculative ASX stock could rise 70%July 17, 2024 | globenewswire.comOpthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory BoardJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 14, 2024 | globenewswire.comOpthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement OfferJune 18, 2024 | globenewswire.comOpthea A$55.0m (US$36.9m¹) Retail Entitlement Offer OpensJune 13, 2024 | globenewswire.comOpthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)June 11, 2024 | globenewswire.comOpthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)June 3, 2024 | globenewswire.comOpthea To Present at Clinical Trials at the Summit MeetingJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 28, 2024 | finanznachrichten.deOpthea Limited: Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMDMay 28, 2024 | theglobeandmail.com2 Stocks Under $10 Wall Street Says Are 'Strong Buys'May 28, 2024 | globenewswire.comOpthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMDMay 25, 2024 | msn.comCRITERION: Looking for a clinical approach to predicting trial outcomes? AI is there for youMay 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Oculis Holding (OCS)May 9, 2024 | msn.comThese 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says OppenheimerMay 8, 2024 | markets.businessinsider.comOptiva Awarded ISO 27001 Certification Demonstrating Commitment to CybersecurityMay 1, 2024 | finance.yahoo.comOpthea Announces Upcoming Presentations at the Retina World Congress 2024May 1, 2024 | globenewswire.comOpthea Announces Upcoming Presentations at the Retina World Congress 2024See More Headlines Receive OPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Next Earnings (Estimated)8/29/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OPT CUSIPN/A CIK1815620 Webwww.opthea.com Phone61-3-9826-0399FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$16.00 Low Stock Price Target$12.00 Potential Upside/Downside+536.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$110,000.00 Price / Sales1,168.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.10) per share Price / Book-22.00Miscellaneous Outstanding Shares58,400,000Free Float56,526,000Market Cap$128.48 million OptionableNot Optionable Beta1.12 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Megan Baldwin M.A.I.C.D. (Age 49)MAICD, Ph.D., Founder, Chief Innovation Officer & Executive Director Comp: $599.73kMs. Judith J. Robertson B.A. (Age 63)M.B.A., Chief Commercial Officer Comp: $588.59kMs. Karen Adams CPA (Age 52)VP of Finance & Company Secretary Comp: $305.14kDr. Frederic Guerard M.S. (Age 51)Pharm.D., Chief Executive Officer Mr. Peter F. Lang M.B.A. (Age 51)Chief Financial Officer Ms. Sarika Gulhar Ph.D.Executive Director of Human ResourcesDr. Michael Gerometta Ph.D. (Age 59)Head of Chemistry, Manufacturing & Controls Development Comp: $132.72kMr. Bruno Gagnon BPHARM (Age 55)M.Sc., Senior Vice President of Global Clinical Operations Dr. Kenneth SallChief Medical OfficerDr. Fang Li Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATEProKidneyNASDAQ:PROKAnavex Life SciencesNASDAQ:AVXLVoyager TherapeuticsNASDAQ:VYGRKyverna TherapeuticsNASDAQ:KYTXView All CompetitorsInstitutional OwnershipBaker BROS. Advisors LPSold 410,819 shares on 5/15/2024Ownership: 3.729%View All Institutional Transactions OPT Stock Analysis - Frequently Asked Questions How have OPT shares performed this year? Opthea's stock was trading at $2.95 at the beginning of the year. Since then, OPT shares have decreased by 24.1% and is now trading at $2.24. View the best growth stocks for 2024 here. When did Opthea IPO? Opthea (OPT) raised $161 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 9,300,000 shares at $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers. How do I buy shares of Opthea? Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
